NIOX NIOX Group Plc
NIOX Group Plc engages in the design, development, and commercialization of medical devices for the diagnosis, monitoring, and management of asthma and COPD worldwide. The company offers NIOX VERO, a non-invasive and point-of-care system that comprises a small portable device, sensors, individual disposable mouthpieces, and breathing handles for the measurement of fractional exhaled nitric oxide (FeNO) level in patients. The company was formerly known as Circassia Group Plc and changed its name to NIOX Group Plc in September 2022. NIOX Group Plc was incorporated in 2006 and is headquartered in Oxford, the United Kingdom.…
Industry Peers
Medical DevicesKey Statistics
About NIOX Group (LON: NIOX)
›
NIOX Group (LON: NIOX) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 97 employees.
The shares were at 59.40 GBp on 19 November 2026, down 15.6% over 52 weeks. Its 52-week range is 53.84 GBp to 80.00 GBp: the price is 25.7% below the high and 10.3% above the low.
At a market capitalisation of 240.73M GBP, it trades at 29.7 times trailing earnings and 16.9 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.6, a premium of 16% for NIOX. It pays a dividend yielding 2.54% (it pays out 95% of its earnings), against a median of 2.36% among the dividend payers in that peer group.
NIOX Group reports return on equity of 10.4%, an operating margin of 21.9% and revenue down 4.8% year over year.
It holds more cash than debt, a net cash position of 16.10M GBP. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 5 analysts cover the stock; their mean price target of 82.40 GBp is 38.7% above the current price. The next earnings report is expected on 23 March 2027.